K 102
Alternative Names: K-102Latest Information Update: 28 Jan 2023
At a glance
- Originator Kashiv BioSciences
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in India (PO, Controlled release)
- 20 Dec 2019 Phase-I clinical trials in Parkinson's disease in India (PO, Controlled release)
- 09 Sep 2019 Kashiv Bioscience initiates a phase I trial in Parkinson's disease in India (PO, Controlled release) (CTRI/2019/09/021093)